

Cancer Targeted Therapy-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/C77CC45375E8EN.html>

Date: May 2018

Pages: 156

Price: US\$ 3,480.00 (Single User License)

ID: C77CC45375E8EN

Abstracts

Report Summary

Cancer Targeted Therapy-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Targeted Therapy industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Cancer Targeted Therapy 2013-2017, and development forecast 2018-2023

Main market players of Cancer Targeted Therapy in EMEA, with company and product introduction, position in the Cancer Targeted Therapy market

Market status and development trend of Cancer Targeted Therapy by types and applications

Cost and profit status of Cancer Targeted Therapy, and marketing status

Market growth drivers and challenges

The report segments the EMEA Cancer Targeted Therapy market as:

EMEA Cancer Targeted Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Cancer Targeted Therapy Market: Product Type Segment Analysis

(Consumption Volume, Average Price, Revenue, Market Share and Trend
2013-2023):

Tumor Antigens As Targets of Antibodies
Development of Antibodies for Clinical Purposes
Complement Dependent Cytotoxicity (CDC)
Signal Transduction Changes

EMEA Cancer Targeted Therapy Market: Application Segment Analysis (Consumption
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital
Clinic
Other

EMEA Cancer Targeted Therapy Market: Players Segment Analysis (Company and
Product introduction, Cancer Targeted Therapy Sales Volume, Revenue, Price and
Gross Margin):

Advaxis
Bind Therapeutics
Boehringer Ingelheim
Bristol Mayer Squibb
Celldex Therapeutics
Dendreon Corporation
Eli Lilly
GalaxoSmithKline
Galena Biopharma
Genetech
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
Johnson & Johnson
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Merck
Novartis
Peregrine Pharmaceuticals
Pfizer
Roche
Sanofi

Seattle Genetics
Teva

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF CANCER TARGETED THERAPY

- 1.1 Definition of Cancer Targeted Therapy in This Report
- 1.2 Commercial Types of Cancer Targeted Therapy
 - 1.2.1 Tumor Antigens As Targets of Antibodies
 - 1.2.2 Development of Antibodies for Clinical Purposes
 - 1.2.3 Complement Dependent Cytotoxicity (CDC)
 - 1.2.4 Signal Transduction Changes
- 1.3 Downstream Application of Cancer Targeted Therapy
 - 1.3.1 Hospital
 - 1.3.2 Clinic
 - 1.3.3 Other
- 1.4 Development History of Cancer Targeted Therapy
- 1.5 Market Status and Trend of Cancer Targeted Therapy 2013-2023
 - 1.5.1 EMEA Cancer Targeted Therapy Market Status and Trend 2013-2023
 - 1.5.2 Regional Cancer Targeted Therapy Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Cancer Targeted Therapy in EMEA 2013-2017
- 2.2 Consumption Market of Cancer Targeted Therapy in EMEA by Regions
 - 2.2.1 Consumption Volume of Cancer Targeted Therapy in EMEA by Regions
 - 2.2.2 Revenue of Cancer Targeted Therapy in EMEA by Regions
- 2.3 Market Analysis of Cancer Targeted Therapy in EMEA by Regions
 - 2.3.1 Market Analysis of Cancer Targeted Therapy in Europe 2013-2017
 - 2.3.2 Market Analysis of Cancer Targeted Therapy in Middle East 2013-2017
 - 2.3.3 Market Analysis of Cancer Targeted Therapy in Africa 2013-2017
- 2.4 Market Development Forecast of Cancer Targeted Therapy in EMEA 2018-2023
 - 2.4.1 Market Development Forecast of Cancer Targeted Therapy in EMEA 2018-2023
 - 2.4.2 Market Development Forecast of Cancer Targeted Therapy by Regions 2018-2023

CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Cancer Targeted Therapy in EMEA by Types
 - 3.1.2 Revenue of Cancer Targeted Therapy in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Cancer Targeted Therapy in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Cancer Targeted Therapy in EMEA by Downstream Industry

4.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Major Countries

4.2.1 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Europe

4.2.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Middle East

4.2.3 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Africa

4.3 Market Forecast of Cancer Targeted Therapy in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER TARGETED THERAPY

5.1 EMEA Economy Situation and Trend Overview

5.2 Cancer Targeted Therapy Downstream Industry Situation and Trend Overview

CHAPTER 6 CANCER TARGETED THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

6.1 Sales Volume of Cancer Targeted Therapy in EMEA by Major Players

6.2 Revenue of Cancer Targeted Therapy in EMEA by Major Players

6.3 Basic Information of Cancer Targeted Therapy by Major Players

6.3.1 Headquarters Location and Established Time of Cancer Targeted Therapy Major Players

6.3.2 Employees and Revenue Level of Cancer Targeted Therapy Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 CANCER TARGETED THERAPY MAJOR MANUFACTURERS

INTRODUCTION AND MARKET DATA

7.1 Advaxis

7.1.1 Company profile

7.1.2 Representative Cancer Targeted Therapy Product

7.1.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Advaxis

7.2 Bind Therapeutics

7.2.1 Company profile

7.2.2 Representative Cancer Targeted Therapy Product

7.2.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bind Therapeutics

7.3 Boehringer Ingelheim

7.3.1 Company profile

7.3.2 Representative Cancer Targeted Therapy Product

7.3.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim

7.4 Bristol Mayer Squibb

7.4.1 Company profile

7.4.2 Representative Cancer Targeted Therapy Product

7.4.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bristol Mayer Squibb

7.5 Celldex Therapeutics

7.5.1 Company profile

7.5.2 Representative Cancer Targeted Therapy Product

7.5.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Celldex Therapeutics

7.6 Dendreon Corporation

7.6.1 Company profile

7.6.2 Representative Cancer Targeted Therapy Product

7.6.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Dendreon Corporation

7.7 Eli Lilly

7.7.1 Company profile

7.7.2 Representative Cancer Targeted Therapy Product

7.7.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Eli Lilly

7.8 GalaxoSmithKline

7.8.1 Company profile

7.8.2 Representative Cancer Targeted Therapy Product

7.8.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of

GalaxoSmithKline

7.9 Galena Biopharma

7.9.1 Company profile

7.9.2 Representative Cancer Targeted Therapy Product

7.9.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Galena

Biopharma

7.10 Genetech

7.10.1 Company profile

7.10.2 Representative Cancer Targeted Therapy Product

7.10.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of

Genetech

7.11 ImmunoCellular Therapeutics

7.11.1 Company profile

7.11.2 Representative Cancer Targeted Therapy Product

7.11.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of

ImmunoCellular Therapeutics

7.12 ImmunoGen

7.12.1 Company profile

7.12.2 Representative Cancer Targeted Therapy Product

7.12.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of

ImmunoGen

7.13 Inovio Pharmaceuticals

7.13.1 Company profile

7.13.2 Representative Cancer Targeted Therapy Product

7.13.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Inovio

Pharmaceuticals

7.14 Johnson & Johnson

7.14.1 Company profile

7.14.2 Representative Cancer Targeted Therapy Product

7.14.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Johnson

& Johnson

7.15 NeoStem Oncology

7.15.1 Company profile

7.15.2 Representative Cancer Targeted Therapy Product

7.15.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of

NeoStem Oncology

7.16 NewLink Genetics

7.17 Northwest Biotherapeutics

7.18 Merck

- 7.19 Novartis
- 7.20 Peregrine Pharmaceuticals
- 7.21 Pfizer
- 7.22 Roche
- 7.23 Sanofi
- 7.24 Seattle Genetics
- 7.25 Teva

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER TARGETED THERAPY

- 8.1 Industry Chain of Cancer Targeted Therapy
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER TARGETED THERAPY

- 9.1 Cost Structure Analysis of Cancer Targeted Therapy
- 9.2 Raw Materials Cost Analysis of Cancer Targeted Therapy
- 9.3 Labor Cost Analysis of Cancer Targeted Therapy
- 9.4 Manufacturing Expenses Analysis of Cancer Targeted Therapy

CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER TARGETED THERAPY

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Cancer Targeted Therapy-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/C77CC45375E8EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C77CC45375E8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970